Geode Capital Management LLC Sells 12,878 Shares of Haemonetics Co. (NYSE:HAE)

Geode Capital Management LLC lowered its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,181,049 shares of the medical instruments supplier's stock after selling 12,878 shares during the quarter. Geode Capital Management LLC owned about 2.35% of Haemonetics worth $92,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Whittier Trust Co. bought a new stake in shares of Haemonetics during the fourth quarter valued at approximately $62,000. Parkside Financial Bank & Trust grew its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the period. AlphaQuest LLC lifted its position in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV boosted its stake in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares in the last quarter. Finally, HighTower Advisors LLC grew its holdings in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HAE. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Needham & Company LLC dropped their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Trading Down 1.8 %

HAE stock traded down $1.07 during mid-day trading on Tuesday, reaching $58.35. 236,837 shares of the stock traded hands, compared to its average volume of 686,306. Haemonetics Co. has a one year low of $55.30 and a one year high of $97.97. The stock has a market capitalization of $2.93 billion, a PE ratio of 22.97, a PEG ratio of 1.11 and a beta of 0.41. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The business has a 50-day moving average price of $63.36 and a two-hundred day moving average price of $73.29.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.